Evidence map›Paper›PMID 42501322›Full record

ArticleFASEB journal : official publication of the Federation of American Societies for Experimental Biology2026

Syringaresinol Attenuates Aging-Associated Ferroptosis-Relevant Stress Through an HIF-1α-GPX4 Defense Axis.

Ya-Ping Li, Fei-Hong Huang, Meng-Ting Wu, Meng-Yi Chen, Yong-Ping Wen, Xiang Li, Lu Yu, An-Guo Wu, Jian-Ming Wu, Xiao-Gang Zhou

Abstract read
In one paragraph

Article in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ya-Ping LiSichuan Key Medical Laboratory of New Drug Discovery and Drugability Evaluation, Luzhou Key Laboratory of Activity Screening and Druggability Evaluation for Chinese Materia Medica, School of Pharmacy, Southwest Medical University, Luzhou, Sichuan, China.
Fei-Hong HuangSichuan Key Medical Laboratory of New Drug Discovery and Drugability Evaluation, Luzhou Key Laboratory of Activity Screening and Druggability Evaluation for Chinese Materia Medica, School of Pharmacy, Southwest Medical University, Luzhou, Sichuan, China.
Meng-Ting WuCollege of Food and Bioengineering, Chengdu University, Chengdu, Sichuan, China.
Meng-Yi ChenCollege of Food and Bioengineering, Chengdu University, Chengdu, Sichuan, China.
Yong-Ping WenCollege of Food and Bioengineering, Chengdu University, Chengdu, Sichuan, China.
Xiang LiSichuan Key Medical Laboratory of New Drug Discovery and Drugability Evaluation, Luzhou Key Laboratory of Activity Screening and Druggability Evaluation for Chinese Materia Medica, School of Pharmacy, Southwest Medical University, Luzhou, Sichuan, China.
Lu YuSichuan Key Medical Laboratory of New Drug Discovery and Drugability Evaluation, Luzhou Key Laboratory of Activity Screening and Druggability Evaluation for Chinese Materia Medica, School of Pharmacy, Southwest Medical University, Luzhou, Sichuan, China.
An-Guo WuSichuan Key Medical Laboratory of New Drug Discovery and Drugability Evaluation, Luzhou Key Laboratory of Activity Screening and Druggability Evaluation for Chinese Materia Medica, School of Pharmacy, Southwest Medical University, Luzhou, Sichuan, China.
Jian-Ming WuSichuan Key Medical Laboratory of New Drug Discovery and Drugability Evaluation, Luzhou Key Laboratory of Activity Screening and Druggability Evaluation for Chinese Materia Medica, School of Pharmacy, Southwest Medical University, Luzhou, Sichuan, China.
Xiao-Gang ZhouSichuan Key Medical Laboratory of New Drug Discovery and Drugability Evaluation, Luzhou Key Laboratory of Activity Screening and Druggability Evaluation for Chinese Materia Medica, School of Pharmacy, Southwest Medical University, Luzhou, Sichuan, China.ORCID https://orcid.org/0000-0002-2574-3973

Funding

The Central Nervous System Product Research and Development Key Laboratory of Sichuan Province, Sichuan Credit Pharmaceutical CO., Ltd. 260001-01SZThe Key Laboratory of Narcotics Control Technology of Liaoning Province, People's Republic of China LNJD2025-03The Science and Technology Strategic Cooperation Programs of Luzhou Municipal People's Government and Southwest Medical University 2025LZXNYDJC17
6 · The paper itself

Abstract

Ferroptosis contributes to aging-associated functional decline, yet compounds with robust organismal efficacy and defined upstream regulatory mechanisms remain limited. Here, we established a diethyl maleate (DEM)-induced glutathione depletion model in wild-type (N2) Caenorhabditis elegans as a survival-based screening platform and identified syringaresinol (Syr) as a leading hit from an in-house small-molecule library. In nematodes, Syr improved survival under DEM challenge, reduced lipid peroxidation, reactive oxygen species (ROS), and malondialdehyde levels, and alleviated age-associated oxidative lipid stress and iron imbalance during natural aging, accompanied by extended lifespan and improved healthspan-related phenotypes. In primary human foreskin fibroblasts, Syr conferred dose-dependent protection against RSL3- or erastin-induced ferroptosis, preserved cellular integrity, suppressed lipid peroxidation and ROS, and restored expression of GPX4, SLC7A11, and ferritin. In two senescence models, Syr also attenuated senescence-associated phenotypes and ferroptosis-related oxidative lipid stress, concomitant with recovery of GPX4 expression. Network-based prediction and functional perturbation identified HIF-1α as a candidate mediator of Syr-associated cytoprotection. HIF-1α knockdown weakened Syr-mediated protection and largely prevented GPX4 restoration, whereas GPX4 knockdown did not alter HIF-1α abundance. These findings support a functional HIF-1α-GPX4 defense axis in fibroblasts, while direct transcriptional regulation remains to be clarified. Overall, Syr attenuates ferroptosis-relevant oxidative lipid stress and aging-associated phenotypes in C. elegans and human fibroblast models, supporting further mechanistic and mammalian in vivo validation.

Indexed as

AgingCaenorhabditis elegans ProteinsFerroptosisFuransHypoxia-Inducible Factor 1, alpha SubunitLignansPhospholipid Hydroperoxide Glutathione PeroxidaseAnimalsCaenorhabditis elegansFibroblastsHumansLipid PeroxidationOxidative StressReactive Oxygen SpeciesCaenorhabditis elegans ProteinsFuransHypoxia-Inducible Factor 1, alpha SubunitLignansPhospholipid Hydroperoxide Glutathione PeroxidaseReactive Oxygen SpeciessyringaresinolagingCaenorhabditis elegansferroptosisHIF‐1α/GPX4senescencesyringaresinol

Identifiers

PMID42501322
PMCPMC13401430

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.